Stimuli-responsive hydrogels are an area of active discovery
for
approaches to deliver therapeutics in response to disease-specific
indicators. Glucose-responsive delivery of insulin is of particular
interest in better managing diabetes. Accordingly, hydrogels have
been explored as platforms that enable both a rate and dose of insulin
release aligning with the real-time physiological disease state; materials
often include glucose sensing by dynamic-covalent cross-linking between
phenylboronic acids (PBAs) and diols, with competition from ambient
glucose reducing cross-link density of the material and accelerating
release of encapsulated insulin. Yet, these materials historically
have challenges with insulin leakage, offer limited glucose-responsive
release of the insulin payload, and require unreasonably high injection
pressures for syringe administration. Here, a thermogel platform prepared
from temperature-induced micelles formed into a network by PBA–Diol
cross-linking is optimized using a formulation-centered approach to
maximize glucose-responsive insulin delivery. Importantly, the dual-responsive
nature of this platform enables a low-viscosity sol at ambient temperature
for facile injection, solidifying into a stable viscoelastic hydrogel
network once in the body. The final optimized formulation affords
acceleration in insulin release in response to glucose and enables
single dose blood glucose control in diabetic rodents when subjected
to multiple glucose challenges.